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Abstract
The influenza A viruses genome comprises eight single-stranded RNA segments of negative polarity. Each one is included in a
ribonucleoprotein particle (vRNP) containing the polymerase complex and a number of nucleoprotein (NP) monomers. Viral
RNA replication proceeds by formation of a complementary RNP of positive polarity (cRNP) that serves as intermediate to
generate many progeny vRNPs. Transcription initiation takes place by a cap-snatching mechanism whereby the polymerase
steals a cellular capped oligonucleotide and uses it as primer to copy the vRNP template. Transcription termination occurs
prematurely at the polyadenylation signal, which the polymerase copies repeatedly to generate a 39-terminal polyA. Here we
studied the mechanisms of the viral RNA replication and transcription. We used efficient systems for recombinant RNP
transcription/replication in vivo and well-defined polymerase mutants deficient in either RNA replication or transcription to
address the roles of the polymerase complex present in the template RNP and newly synthesised polymerase complexes
during replication and transcription. The results of trans-complementation experiments showed that soluble polymerase
complexes can synthesise progeny RNA in trans and become incorporated into progeny vRNPs, but only transcription in cis
could be detected. These results are compatible with a new model for virus RNA replication, whereby a template RNP would
be replicated in trans by a soluble polymerase complex and a polymerase complex distinct from the replicative enzyme would
direct the encapsidation of progeny vRNA. In contrast, transcription of the vRNP would occur in cis and the resident
polymerase complex would be responsible for mRNA synthesis and polyadenylation.
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Introduction
The influenza A viruses are the causative agents of yearly
epidemics of respiratory disease and occasionally more severe
pandemics [1]. The latter are the consequence of transfers from
the avian virus reservoir to humans by either genetic reassortment
or direct adaptation [2]. Thus, current occasional infections of
humans with highly pathogenic H5N1 avian strains have raised
fears about a possible new pandemic of great severity.
The influenza A viruses belong to the family Orthomyxoviridae and
posses a single-stranded, negative-polarity RNA genome made up
by 8 RNA segments, that form ribonucleoprotein (RNP)
complexes by association to the polymerase and the nucleoprotein
(NP). Such RNPs are independent molecular machines responsible
for transcription and replication of each virus gene and contain an
RNA-dependent RNA polymerase composed by the PB1, PB2
and PA subunits [3]. The polymerase complex recognises the
RNA promoter comprising both 59-terminal and 39-terminal
sequences of each segment, by preferentially binding the 59-
terminal end [4–6], and in this way stabilises a supercoiled
conformation of the RNPs [7].
Upon infection of susceptible cells, the parental RNPs are first
transcribed in the nucleus (primary transcription). Transcription
initiation takes place by a cap-snatching process whereby the viral
polymerase recognises the cap structure of cellular pre-mRNAs in
the nucleus, cleaves these some 15 nt downstream the cap and
utilises such capped-oligonucleotides as primers to copy the virus
template RNA [8]. Transcription finalises by reiterative copy of
the virus polyadenylation signal, an oligo-U sequence located close
to the 59-end of the template [9,10]. Synthesis of new virus
proteins is required to proceed to RNP replication [11], that takes
place first by the generation of complementary RNPs (cRNPs).
These RNPs are structurally analogous to those present in the
virions (vRNPs) but contain complete positive-polarity copies of
the virus RNA segments, that are neither capped nor polyadenyl-
ated. The structural differences between the vRNP transcription
and replication products (mRNAs and cRNPs) led to the proposal
of a transcription-to-replication switch by which the parental
RNPs would change from capped-RNA-dependent to de novo
initiation, from polyadenylation to full copy of the template, and in
addition would induce encapsidation of the RNA product into new
RNPs (reviewed in [12]. Such notion has been challenged recently
by a new model proposing that parental vRNPs can directly
synthesise cRNA but require newly synthesised polymerase and
NP to stabilise the product in the form of cRNPs [13]. The cRNPs
accumulate to low levels but serve as efficient templates for the
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transcribed (secondary transcription) and eventually be incorpo-
rated into progeny virions [3].
Much information has been obtained during recent years on
structural aspects of the RNPs [14,15] (R. Coloma, unpublished
results) and their components, like the NP [16,17], the polymerase
complex [18,19] and specific domains of the polymerase subunits
[20–24]. Likewise, a number of host cell factors have been
identified that may play important roles in the transcription and
replication processes [25–34]. However, much remains to be
learned about the detailed mechanisms for RNP transcription and
replication. For instance, it is not clear whether the polymerase
complex present in the template RNP is able to synthesise the
progeny vRNA or whether the replicative complex directs the
encapsidation of progeny RNA it into a new vRNP. Likewise, it
has been assumed that the polymerase complex present in the
vRNP accounts for viral mRNA synthesis, but it is not clear
whether other vRNPs or other soluble polymerase complexes
perform this step in trans. In this report we used efficient in vivo
recombinant replication and transcription systems and defined
polymerase mutants specifically affected in either transcription or
replication to answer these questions. Our results are consistent
with a new model whereby polymerase complexes not associated
to the template cRNP are responsible for the replicative synthesis
of vRNPs in trans and polymerase complexes distinct from the
replicative one specify the encapsidation of viral RNAs. On the
contrary, no vRNP transcription could be detected by other RNP
or a soluble polymerase complex in trans, suggesting that it takes
place by the activity of the RNP-associated polymerase complex.
Results
The experimental approach
To gather information on the mechanisms of influenza virus
transcription and replication we have adopted a genetic trans-
complementation approach. This is based on the ability to
reconstitute in vivo an efficient transcription-replication system
that mimic these steps of the infection cycle and is more amenable
to experimental manipulations [15,35]. Furthermore, the vRNP
products can be efficiently purified, their structural and biological
properties can be easily analysed [14,18,20] and they can in turn
be used as templates for further rounds of in vivo replication.
Essential for these approaches is the availability of well-defined
mutants to be used as genetic markers. We have earlier described
point mutants in the PB2 subunit of the viral polymerase that are
defective in viral RNA replication but fully efficient in virus
transcription [36]. Likewise, we have recently reported polymerase
PB2 mutants that are affected in the cap-binding activity and
hence are defective in cap-snatching, but retain their capacity to
replicate virus RNPs [20].
A polymerase complex distinct from the replicative
enzyme becomes associated in trans to the newly
synthesised vRNA
Using the approaches indicated above we first addressed the
question whether the replication deficiency of point mutants
within the N-terminus of PB2 [36] could be rescued in trans by co-
expression of PB2 point mutants defective in cap-binding [20].
Cultures of HEK293T cells were co-transfected with plasmids
encoding PB1, PA, NP and a deleted NS virus replicon (clone 23,
248 nt in length; [14,15]). In addition, either PB2wt or PB2
mutants R142A or F130A (replication-defective) or mutant E361A
(transcription-defective) were co-expressed. Alternatively, pair wise
combinations of these PB2 mutants were co-expressed
(R142A+E361A and F130A+E361A). Among the PB2 proteins
expressed, either wt or the replication-defective mutants R142A or
F130A were His-tagged at the C-terminus, a modification that
does not alter their biological activity and allows the efficient
purification of the in vivo RNP replication progeny [18]. The
expression levels of all PB2 mutants were shown to be similar to
that of PB2wt (Fig. S1) and the untagged PB2wt was used as a
control for purification (see diagram of the experimental setting in
Fig. 1A). After incubation, the cell extracts were used for Ni
2+-
NTA-agarose purification as described in Materials and Methods
and the accumulation of progeny RNPs was determined by means
of Western-blot assays using anti-NP sera. The purification of the
complete RNPs was verified by Western-blot with antibodies
specific for PB2 and PA (Fig. 1B). This strategy allows measuring
the replication capacity of the RNPs formed in vivo, as omitting
any RNP element or using a defective point mutant leads to
undetectable RNP accumulation [15,36,37]. Amplification of virus
RNPs was expected for wt and mutant polymerase containing
transcription-defective PB2 (E361A), but not for those containing
replication-defective PB2 (R142A and F130A). However, since no
tag is present in the former mutant, only RNPs derived from
cultures containing PB2His were expected in the Ni
2+-NTA-
agarose purified material. This was indeed the case, as shown in
Fig. 1B. If the transcription-defective polymerase were able to
rescue in trans the defect in replication of polymerase mutants
R142A or F130A, one would expect the accumulation and
purification of RNPs containing these mutant PB2. The results
obtained by the co-expression of pairs of replication- and
transcription-defective polymerases indicate that such prediction
is hold (Fig. 1B). The transcription-defective mutant could rescue
both R142A and F130A alleles and similar rescue was obtained
when other transcription-defective mutants, like H357A, K370A,
F404A [20] were used (Fig. S2).
The progeny RNPs contained the replication-defective PB2
allele, since (i) they could be purified by Ni
2+-NTA-agarose
chromatography and (ii) the mobility of the PB2 subunit in the
Western-blot assay corresponded to the His-tagged subunit and
not to the untagged one. It is important to mention that only His-
Author Summary
The influenza A viruses produce annual epidemics and
occasional pandemics of respiratory disease. There is great
concern about a potential new pandemic being caused by
presently circulating avian influenza viruses, and hence
increasing interest in understanding how the virus
replicates its genome. This comprises eight molecules of
RNA, each one bound to a polymerase complex and
encapsidated by multiple copies of the nucleoprotein, in
the form of ribonucleoprotein complexes (RNPs). These
structures are responsible for virus RNA replication and
transcription but the detailed mechanisms of these
processes are not fully understood. We report here the
results of genetic complementation experiments using
proficient in vitro and in vivo recombinant systems for
transcription and replication, and polymerase point
mutants that are either transcription-defective or replica-
tion-defective. These results are compatible with a new
model for virus replication whereby a polymerase distinct
from that present in the parental RNP is responsible for
RNA replication in trans and the progeny RNP is associated
to a polymerase distinct from that performing replication.
In contrast, transcription is carried out in cis by the
polymerase resident in the RNP.
Model for Influenza Transcription and Replication
PLoS Pathogens | www.plospathogens.org 2 May 2009 | Volume 5 | Issue 5 | e1000462Figure 1. Intracistronic polymerase complementation during influenza virus RNA replication. (A) Cultures of HEK293T cells were
transfected with plasmids expressing a virus-like replicon of 248 nt, the NP and various combinations of the polymerase subunits as indicated in the
diagram. The potential RNPs that could be generated are also depicted in the diagram, as well as the expected progeny RNPs, depending on the
replication phenotype of the polymerase mutants used. (B) The progeny RNPs were purified from total cell extracts over Ni
2+-NTA-agarose resin and
analysed by Western-blot with anti-NP antibodies. The top panel presents the accumulation of NP in the total cell extract whereas the bottom panel
shows the NP accumulation of purified RNPs. The integrity of the purified RNPs is verified by Western-blot using anti-PB2 and anti-PA antibodies. In
the bottom graph the average NP accumulation and standard deviation of three independent complementation experiments are presented as
percent of maximal value.
doi:10.1371/journal.ppat.1000462.g001
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untagged counterpart, indicating that no transcription-defective
polymerase was co-purified (Fig. 1B). Furthermore, the phenotype
of the rescued RNPs was tested by determination of their in vitro
transcription activity (Fig. 2). Since the transcription-defective
mutants had alterations in their cap-binding pocket, they show low
in vitro transcription activity when a mRNA is used as a cap-
donor, whereas cap-independent transcription is observed with a
general primer as the dinucleotide ApG [20]. The transcription
activity profile of rescued RNPs using ApG or b-globin mRNA as
primers was identical to that of wt RNPs, as expected, and not to
that of mutant E361A, that is unable to use b-globin as primer
[20] (Fig. 2 and Fig. S3).
In the experimental approach used, the reconstitution of a RNP
from the viral proteins and genomic RNA has to take place first
and its subsequent amplification would account for the bulk of
RNPs that can be purified from the transfected cells. Since a RNP
template with the replication-defective polymerase does not
replicate [36], only transcription-deficient polymerase could
perform RNP replication. The results obtained (Figs. 1, 2)
demonstrate that a polymerase complex distinct from that
responsible for RNP replication (replication-defective versus
transcription-defective) is incorporated into the progeny vRNP
and suggest that a replication-defective polymerase can direct the
encapsidation of the progeny vRNA, i.e. can bind the 59-terminus
of newly synthesised vRNA and direct the incorporation of NP
monomers into the progeny vRNP. It could be argued that the
incorporation of the replication-defective polymerase to the
progeny RNP might occur by exchange with replication-
competent during purification in vitro. Two lines of evidence
argue against such possibility: (i) Our transcription experiments
verify that the polymerase present in an RNP complex is stably
bound (see below) and (ii) The data reported by Wreede et al. [38]
suggest that the binding of a polymerase complex to the 59-
terminal sequence of viral RNA can not competed by a pre-
expressed polymerase. In fact, the average rescue efficiency
obtained (55+/218%) (Figs. 1, 2) was very high, and is in line
with the possibility that both types of soluble polymerase
complexes, transcription- and replication-deficient, are incorpo-
rated in the progeny viral RNA, around half of which would not
be detected because are not His-tagged.
Non-resident polymerase complexes are responsible for
the synthesis of vRNA in trans
The rescue of viral RNPs containing the mutant R142A
polymerase complex, as described above, enabled us to purify
these RNPs and use them as templates for a second in vivo
reconstitution experiment in which instead of a template RNA we
introduced the rescued and purified R142A mutant RNPs in the
system. This strategy ensured that only replication-defective RNPs
are used as templates for in vivo replication and allowed us to ask
whether the resident polymerase complex or a distinct, soluble
polymerase is responsible for replication of RNPs in vivo. The
concentration and biological activity of these purified RNPs was
first controlled by Western-blot and in vitro transcription. The
results are presented in Fig. 3B and show that higher yields were
obtained for RNPs containing the E361A mutation in PB2 than
those containing the R142A mutation. This was expected, as the
latter could only be amplified by trans-complementation (see Fig. 1
above). The transcription phenotype of these purified RNPs was in
agreement with the mutations present in PB2 (Fig. 3B, right panel).
Therefore, cultures of HEK293T cells were co-transfected with
purified RNPs containing either the R142A mutation or the
E361A mutation in PB2, plasmids encoding PB1, PA, NP and a
plasmid encoding either PB2-His R142A (replication-defective) or
PB2-His E361A (transcription-defective) (see Fig. 3A for a diagram
of the experimental setting). As controls, the RNPs were co-
transfected with empty pCMV vector or the expression plasmids
were transfected in the absence of template RNPs. The
intracellular accumulation of progeny RNPs was determined by
Ni
2+-NTA-agarose purification, Western-blot and in vitro tran-
scription as indicated above and the results are presented in Fig. 3C
and Fig. 4. The cultures co-transfected with RNPs E361A and
plasmids including PB2 E361A (Fig. 3C; RNP361-Pol361) served
as positive control and, indeed gave rise to the accumulation of
RNPs to levels similar to the standard, wt system (see Fig. 1B,
HisPB2). No background was observed when template RNPs were
transfected (Fig. 3C; RNP142/CMV, RNP361/CMV). A fraction
of the NP expressed was retained in the Ni
2+-NTA-agarose resin
(Fig. 3C; Pol142, Pol361) and defined the background level of the
purification protocol (but see Fig. 4 below). The co-transfection of
RNPs containing mutation PB2 R142A and the same mutant
plasmids yielded no increase above background in the level of
purified RNPs (Fig. 3C; RNP142/Pol142) but the mixed
transfection of RNPs with the mutation PB2 R142A and the
expression plasmids with mutation PB2 E361A led to a high level
of replication (around 80% of control values) (Fig. 3C; RNP142/
Pol361). To verify these results and to determine the polarity of the
progeny RNA, similar experiments were carried out and the RNA
present in the purified his-RNPs was analysed by hybridisation
with positive- and negative-polarity RNA probes comprising the
NS sequence. The results reinforced the data obtained by
Western-blot and indicated that most of the progeny RNPs are
vRNPs (Fig. 4), as previously reported [15]. The accumulation and
phenotype of the progeny RNPs was also verified by in vitro
transcription using either ApG or b-globin as primers (Fig. 5). The
accumulations observed paralleled those shown in Fig. 3 but the
background levels from samples Pol142, Pol361 and RNP142-
Pol142 were negligible. Much higher activity levels were obtained
with ApG primer, indicating that the progeny RNPs contained
PB2 with mutation E361A. The results presented in Figs. 3 and 4
Figure 2. Phenotype of trans-complemented RNPs. The purified
RNP preparations presented in Fig. 1 were tested for in vitro
transcription primed with either ApG (red) or b-globin mRNA (green).
The data are presented as percent of maximal value and represent the
averages and ranges of two independent complementation experi-
ments. The transcription activities parallel the values of NP accumula-
tion presented in Fig. 1 and show that the rescued RNPs have a wt cap-
snatching phenotype.
doi:10.1371/journal.ppat.1000462.g002
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PLoS Pathogens | www.plospathogens.org 4 May 2009 | Volume 5 | Issue 5 | e1000462Figure 3. Replication of RNPs by a soluble polymerase complex in trans. (A) Cultures of HEK293T cells were transfected with plasmids
expressing the NP and various combinations of the polymerase subunits as indicated in the diagram. In some cases, purified RNPs containing
replication-deficient or transcription-deficient polymerase were also transfected. The expected progeny RNPs are also depicted, depending on the
Model for Influenza Transcription and Replication
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the template RNP can perform the replicative synthesis of viral
RNA. The high level of replication detected by trans-complemen-
tation suggests that virus RNA replication mostly occurs in trans. It
could be argued that the mutation R142A in PB2 might destabilise
the polymerase-promoter complex, allowing the efficient replace-
ment by a polymerase complex containing the E361A mutation.
However, RNPs containing the R142A mutation are as efficient in
transcription as wt RNPs, suggesting that they are not affected in
promoter recognition.
Transcription of vRNPs takes place in cis and cannot be
stimulated by non-resident polymerase complexes in
trans
It is well established that vRNPs can transcribe mRNAs in the
absence of any newly synthesised viral proteins (primary
transcription) [39,40] and highly purified recombinant RNPs
can transcribe in vitro [18] (R. Coloma, unpublished results).
However, it is not clear whether transcription takes place
intramolecularly, i.e. in cis, or a RNP can transcribe another
RNP. To test this possibility we reconstituted in vivo two
genetically distinct RNPs, one containing a cat virus replicon
(with the cat negative-polarity ORF flanked by the UTRs of the NS
segment of influenza virus), the other one being the NS deletion
mutant clone 23 [14,15]. Both RNPs contained a His-tagged PB2
subunit to allow purification by affinity chromatography as
indicated above but two PB2 alleles were used, either wt or
mutant E361A, which is defective in the recognition of the cap
structure [20]. Purified RNPs were used either separately or in
combination for in vitro transcription with ApG or b-globin as
primers and the transcription products were analysed by
denaturing polyacrylamide gel electrophoresis and autoradiogra-
phy. The results are presented in Fig. 6. As expected, the purified
wt RNPs were active, both when ApG or b-globin were used as
primers (Fig. 6A). The RNPs containing the mutation PB2 E361A
could transcribe mRNA with ApG as primer, but did so less
efficiently when using b-globin mRNA as primer donor (Fig. 6A).
These results allowed us to test whether a purified, wt clone 23
RNP could rescue the transcription activity of mutant E361A cat
RNP in trans, since the mRNA products would be distinguishable
by size (720 nt versus 248 nt). The wild-type cat RNPs could
transcribe efficiently, both when incubated on their own and when
mixed with clone 23 RNPs (Fig. 6B, middle panel). The cat RNPs
containing PB2 E361A only produced background transcription
levels and no increase in the amount of cat mRNA was observed
when wt clone 23 RNP was co-transcribed (Fig. 6B, right panel).
Quantisation of the relevant bands indicated that the increase in
cat transcript in the co-transcription of clone 23 RNP+E361 cat
RNP versus the transcription of E361 cat RNP was less than 3% of
the cat transcript value obtained by co-transcription of clone 23
RNP+wt cat RNP. These results suggest that, at least in vitro, no
transcription in trans among different RNPs takes place.
However, the possibility still persists that a soluble polymerase
complex is able to transcribe a vRNP template in trans. To analyse
this alternative we generated in vivo recombinant RNPs
containing the negative polarity cat virus replicon, purified them
by affinity chromatography as indicated above and used them to
transfect HEK293T cultures. Alternatively, the cultures were co
transfected with the purified cat-containing RNPs and plasmids
expressing the polymerase subunits (see Fig. 7A for a diagram of
the experiment). As no plasmid expressing NP was used, no in vivo
replication of the RNPs can take place [41,42]. Two RNP versions
were used, either wt or transcription-defective (containing PB2
E361A mutant). Three alternative alleles were used to express in
vivo PB2, generating wt polymerase, transcription-defective
E361A or replication-defective R142A polymerase complexes,
and various RNP-polymerase combinations were used in co-
transfection experiments. In this way the experiment would mimic
the situation of primary transcription (transfection of purified
RNPs) or secondary transcription (co-transfection of RNPs with
plasmids expressing the polymerase complex). At 24 hours post-
transfection total cell extracts were prepared and the CAT protein
accumulation was determined by ELISA. To ensure that the
purified RNPs used for transfection were biologically active, two
assays were carried out. First, their transcription activity was
determined in vitro. As shown in Fig. 7B, there was a good
correlation between the concentration of the RNPs, as determined
by Western-blot with anti-NP and anti-PA antibodies, and the
their capacity to synthesise RNA in vitro. Furthermore, the
relative activity when using ApG or b-globin mRNA as primers
verified that the purified mutant RNPs contained the E361A
mutation (Fig. 7B, 361). In addition, the biological activity of the
purified 361 RNPs was verified in vivo, by their co-transfection
with plasmids expressing the polymerase subunits and NP. The
results are presented in Fig. S4 and indicate that they can serve as
templates for replication and transcription in vivo. Expression of
the polymerase subunits did not yield any detectable CAT protein,
as expected (Fig. 7C, Pol wt), but the transfection of wt purified
RNPs lead to clearly measurable CAT accumulation (Fig. 7C,
RNP wt) and co-expression of wt RNPs with wt polymerase did
not lead to any increase of CAT accumulation (Fig. 7C, Pol wt-
RNP wt). As control transfections with CAT-containing cellular
extracts indicated that the carry-over of the protein was in the
range of 10
23 to 10
24 (data not shown), the CAT protein
generated by transfection of wt purified RNPs should represent
primary transcription. In agreement with their transcription-
defective phenotype, transfection of purified mutant 361 RNPs
produced much less CAT accumulation (Fig. 7C, RNP 361). No
significant increase in the level of CAT protein was observed by
co-transfection of the RNPs containing the E361A mutation with
polymerase-expressing plasmids, neither wt nor mutant polymer-
ase and no correlation was observed between the accumulation of
CAT and the phenotype of the polymerase co-expressed (Fig. 7C;
compare Pol wt vs Pol 142 vs Pol 361+RNP 361). These results
indicated that, under the experimental conditions used, no trans-
activation of transcription occurs in vivo.
replication phenotype of the polymerase mutants used. (B) Left panel: The amount of replication-deficient (R142) or transcription-deficient (R361)
RNPs transfected was ascertained by Western-blot with anti-NP and anti-PB2 antibodies. The mobility of molecular weight markers is shown to the
left and the position of PB2 and NP proteins is indicated to the right. Right panel: The transcription phenotype of the RNPs transfected was
determined by in vitro transcription using ApG (ApG) or b-globin mRNA (b-glob) as primers. The panel shows the phosphorimager data. (C) The
progeny RNPs were purified from total cell extracts over Ni
2+-NTA-agarose resin and analysed by Western-blot with anti-NP antibodies. The top panel
presents the accumulation of NP in the total cell extract whereas the bottom panel shows the NP accumulation of purified RNPs. The integrity of the
RNPs is verified by Western-blot using anti-PB2 and anti-PA antibodies. In the bottom graph the average NP accumulation and range of two
independent complementation experiments are presented as percent of maximal value. The transfecting RNPs are denoted as RNP142 or RNP361.
The genotypes of the transfected polymerases are indicated as Pol142 or Pol361. CMV indicates the transfection of empty pCMV plasmid.
doi:10.1371/journal.ppat.1000462.g003
Model for Influenza Transcription and Replication
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The processes of virus RNA replication and transcription usually
require the action of one to several virus-specific proteins, notably the
RNA-dependent RNA polymerase (RdRp), and various host cell
factors (for a review see [43]. To unravel the complex procedures
involved, genetic experimental approaches have been particularly
useful. For example, genetic data have strongly supported the
requirement of RdRp oligomerisation for RNA replication in several
virus groups, like poliovirus [44,45], HCV [46,47] and Sendai virus
[48,49]. Early studies on the dominance of RNA-synthesis negative ts
mutants of VSV suggested that the oligomerisation of virus factors
involved in RNA replication is an essential step in the process [50], a
conclusion that could be also verified in the poliovirus system [51].
More generally, the multimeric nature of complex viral systems, as
the virus particles, has profound consequences in the apparent
phenotype observed [52,53]. In the case of influenza, early data on
the intragenic complementation of mutants affecting the PB1 and PA
proteins suggested the potential role of virus polymerase interactions
in the infectious cycle [54–56] and the recent biochemical evidence
for virus polymerase oligomerisation supported such contention [57].
Here we have taken advantage of the availability of well-established
recombinant systems for RNP replication and transcription and well-
characterised polymerase mutants to address specific questions on the
mechanisms of these processes. Due to the segmented nature of the
influenza virus genome it is essential to use mutant polymerases
having phenotypically distinct mutations in the same subunit, thus
avoiding the problems of reassortment. Hence, we have used point
mutants of polymerase PB2 subunit that abolish RNA replication but
transcribe normally (R142A or F130A) [36] and/or mutants that are
Figure 5. Phenotype of trans-complemented RNPs. The purified
RNP preparations presented in Fig. 3 were tested for in vitro
transcription primed with either ApG (red) or b-globin mRNA (green).
The data are presented as percent of maximal value and represent the
averages and range of two independent complementation experi-
ments. The transfecting RNPs are denoted as RNP142 or RNP361. The
genotypes of the transfected polymerases are indicated as Pol142 or
Pol361. CMV indicates the transfection of empty pCMV plasmid. The
transcription activities parallel the values of NP accumulation presented
in Fig. 3 and show that the rescued RNPs have a cap-snatching
defective phenotype.
doi:10.1371/journal.ppat.1000462.g005
Figure 4. Analysis of the genomic RNA present in purified
RNPs. Cultures of HEK293T cells were transfected with plasmids
expressing the NP and various combinations of the polymerase
subunits and purified RNPs containing either replication-deficient or
transcription-deficient polymerase, as indicated in the diagram of
Fig. 3A. The purified progeny RNPs were purified from total cell extracts
by affinity chromatography over Ni
2+-NTA-agarose and the RNA present
in the purified RNPs was extracted as described under Materials and
Methods. (A) Hybridisation controls. Dilutions of plasmid pHHDNS clone
23, containing the sequence of the RNP replicons used (+), or total yeast
RNA (2) were applied onto a nylon filter as hybridisation controls (from
10
3 to 10
0 ng, as indicated at the top of the figure). Hybridisation was
performed using a positive-polarity or a negative-polarity probe
comprising the full-length insert present in pHHDNS clone 23, thereby
detecting either vRNA or cRNA, respectively. (B) Aliquots of the RNA
present in purified RNPs obtained from cultures transfected with the
mixtures indicated at the bottom of the figure were hybridised in
parallel to the hybridisation controls shown in (A) and the hybridisation
signals were quantitated in a phosphorimager, using the signals in (A)
to standardise the relative hybridisation efficiency of the positive- and
negative-polarity probes. The results for vRNA (blue) and cRNA (orange)
are presented as percent of the maximal signal and represent the
averages and standard deviations of 4 quantisations.
doi:10.1371/journal.ppat.1000462.g004
Model for Influenza Transcription and Replication
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RNA normally (E361A among others) [20]. With these experimental
tools we have asked whether the polymerase complex present in an
RNP actually perform the replicative or transcriptional synthesis of
RNA and whether the polymerase complex present in the progeny
RNP is identical to that performing replicative synthesis of RNA. Our
results will be discussed on the basis of the model presented in Fig. 8,
in which only the replication step cRNP-to-vRNP is presented. The
results shown in Figs. 1 and 2 indicated that two such phenotypically
distinct mutant polymerases can complement to perform viral RNP
replication in vivo and demonstrated that a replication-defective
polymerase can be incorporated into progeny RNPs. These results
are consistent with the model presented in Fig. 8A, step 4, that suggest
that a polymerase complex distinct from that performing replicative
synthesis is involved in the recognition of the 59-end of the progeny
vRNA. This model is also consistent with the results published earlier
indicating that a pre-expressed polymerase can protect newly
synthesised cRNA [13,38]. The identity of the replicative polymerase
complex could be tested by directly transfecting mutant RNPs as
templates for the replication reaction and asking whether co-
expressed replication-defective or transcription-defective polymerase
complexescould carryoutthe replicationprocessintrans.Theresults
shown in Figs. 3 and 4 demonstrated that a polymerase complex
genetically distinguishable from that present in the parental RNP was
able to perform replication and became incorporated into the
progeny RNPs. These results are compatible with the model
presented in Fig. 8A, steps 2–4, whereby a soluble polymerase
complex would interact with that resident in the parental RNP and
gain access to the 39-terminal sequence in the promoter. Such
polymerase-polymerase interaction is supported by the genetic data
presented here, by the intragenic complementation reported earlier
[54,55] and by the oligomerisation of influenza polymerase in vivo
[57]. Although not shown in Fig. 8A, we can not exclude that a host
factor(s) participate in the polymerase-polymerase interaction and in
fact several nuclear factors have been described previously that could
play such a role [25–30,32]. The trans-replication model depicted in
Fig. 8A, steps 2–4 relates to the cRNP-to-vRNP phase in replication.
However, earlier data published on the protection of newly
synthesised cRNA by pre-expressed polymerase would suggest that
the vRNP-to-cRNA phase can occur in cis, since a pre-expressed,
catalytically inactive polymerase allowed the accumulation of cRNA
in cicloheximide-treated, virus-infected cells [13].
According to the model proposed here, the soluble polymerase
complex would act as replicative enzyme by de novo initiation and
elongation through the NP-RNA template (Fig. 8, steps 3–4). We
propose that the 39-end of the parental RNA is used repetitively for
further initiation rounds, thereby leading to several progeny vRNPs
generated from a single cRNP template. For simplicity, the model
presented in Fig. 8A does not show the interaction of the new
incoming replicative complex with the parental polymerase bound to
the 59-end of the template, but such interaction might be required. In
view of our previous evidence on polymerase-polymerase interaction
[57], an appealing possibility is that the replicative polymerase
complexes would oligomerise to form a fixed replication platform
along which the NP-RNA template would move 39-to-59 to generate
Figure 6. Genetically distinct RNPs cannot transcribe recipro-
cally in vitro. (A) Recombinant RNPs were generated by in vivo
amplification as described in Materials and Methods and the legend to
Fig. 1, using either wt (WT) or transcription-defective (E361A)
polymerase. Short (clone 23 -248 nt-), long (CAT -720 nt-) or no (CTRL)
RNA replicons were used. The RNPs were purified by Ni
2+-NTA-agarose
chromatography and their transcription activity was determined. Top
panel shows the phosphorimager data and bottom panel presents the
quantisation, indicating the cap-snatching defective phenotype of RNPs
containing the E361A mutation in PB2. (B) Purified wt (WT CAT) or
E361A mutant RNPs (361 CAT) containing the cat gene were transcribed
in vitro, using b-globin mRNA as primer, either alone or in a mixture
with wt clone 23 RNPs (cl23). The transcription products were purified
and analysed by polyacrylamide-urea denaturing gel electrophoresis.
The mobility of molecular weight markers is shown to the left and the
position of cat and clone 23 transcripts is indicated to the right.
doi:10.1371/journal.ppat.1000462.g006
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PLoS Pathogens | www.plospathogens.org 8 May 2009 | Volume 5 | Issue 5 | e1000462Figure 7. Lack of transcription of RNPs by a soluble polymerase complex in trans. (A) Cultures of HEK293T cells were transfected with
plasmids expressing various combinations of the polymerase subunits as indicated in the diagram. In some cases, purified cat RNPs containing wt or
transcription-deficient polymerase were also transfected. (B) Left panel. The amount of wt (wt) or transcription deficient (361) RNPs transfected was
ascertained by Western-blot with anti-NP and anti-PA antibodies. The mobility of molecular weight markers is shown to the left and the position of
PA and NP proteins is indicated to the right. Right panel. The transcription phenotype of the RNPs transfected was determined by in vitro
transcription using ApG (ApG) or b-globin mRNA (b-globin) as primers. The panel shows the phosphorimager data. (C) The amount of CAT protein
accumulated in the cells was determined by ELISA. The data are presented as percent of the value obtained by transfection of purified wt RNPs and
represent the average and standard deviation of six independent experiments. The 100% value represented corresponds to a concentration of
340 pg/ml of CAT protein.
doi:10.1371/journal.ppat.1000462.g007
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PLoS Pathogens | www.plospathogens.org 9 May 2009 | Volume 5 | Issue 5 | e1000462Figure 8. A model for influenza RNP replication and transcription. (A) Various steps in the process of RNP replication. The coloured NP
indicates the polarity of the templates (brown: positive polarity; green: negative polarity). The parental polymerase complex is denoted by solid
colours while the semi-transparent colouring indicates a newly synthesised complex. See text for details. (B) Various steps in the process of RNP
transcription. The capped primer is depicted as a thick line with a red circle. See text for details.
doi:10.1371/journal.ppat.1000462.g008
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positive-strand RNA viruses [44–47] and would be consistent with
the localised synthesis of influenza virus RNA in the nucleus [58,59].
A critical point in the generation of progeny vRNP is the recognition
and packaging of its newly synthesised 59-end. Our results are
compatible with the proposal that a polymerase complex distinct
from the replicative enzyme can protect the newly synthesised vRNA
(Fig. 8A, step 4) and this event probably represents the sequence-
specific step in the encapsidation of RNA into progeny RNP. The
subsequent incorporation of successive NP monomers would be
directed by polymerase-NP interactions [60], that have been shown
as essential for RNP replication [61,62], as well as by the NP-NP
oligomerisation [17] (R. Coloma, unpublished results). Another
critical point in the replication process is the displacement of the
parental polymerase complex bound to the 59-end of the template, a
step necessary to avoid polyadenylation (see below) and to allow the
complete copy of the RNA. Our results do not permit us to
distinguish whether the elimination of such interaction is transient or
permanent, but an attractive possibility would be that the reiterative
copy of the NP-RNA template on a fixed platform of replicative
polymerases wouldforce the displacement of the parental polymerase
bound to the 59-terminal sequence. Such displacement could be
transient, leading to the replacement of the parental polymerase by
each successive replicative polymerase, or permanent, leading to a
linearised NP-RNA complex (Fig. 8A, step n).
In contrast to the positive complementation obtained for the
replication process, no trans-complementation could be detected
in the transcription assays using either in vitro (Fig. 6) or in vivo
experiments (Fig. 7). In vitro transcription of a recombinant RNP
containing a cap-binding defective polymerase could not be
rescued by a wt RNP holding a template of different length (Fig. 6).
Similar negative results were obtained in vivo, by transfection of a
cap-binding defective RNP and co-expression of wt or replication-
defective but transcriptionally functional polymerase (Fig. 7).
These results are not compatible with the possibility of
transcription among viral RNPs in trans and do not support the
possibility of a soluble polymerase transcribing an independent
RNP. Furthermore, these results indicate a high stability of the
polymerase binding to the RNP structure during the transcription
process, as no polymerase exchange could be functionally
detected. In view of the lack of detectable transcription in trans,
we propose the model presented in Fig. 8B for the generation of
viral mRNAs. The resident polymerase complex would be
transcriptionally activated by recognition of the cap-containing
cellular mRNA and proceed to cap-snatching and elongation of
the virus transcript (Fig. 8B, step 2), but still keeping hold of the 59-
terminal sequence of the promoter [63]. Such process would lead
to a running knot structure with a diminishing loop length (Fig. 8B,
steps 2–4) until the transcribing polymerase reaches the oligo-U
polyadenylation signal [10]. Due to steric hindrance, the
polymerase would stutter around the oligo-U sequence and
generate a 39-terminal polyA (Fig. 8B, step 4). For simplicity, the
model presented in Fig. 8B shows the transcribing RNP in a
linearised form, but the polymerase complex should recognise the
39-terminal side of the promoter at some time later in the process,
in order to recycle and allow further rounds of transcription. This
model for transcription of RNPs in cis is compatible with the fact
that parental RNPs perform primary transcription as a first step in
the infection and with the possibility to rescue virus by transfection
of purified virion and/or recombinant RNPs [64,65]. It also would
fit with the correlation of vRNA and mRNA levels of the various
RNA segments along the infection cycle [66,67].
In summary, using genetically distinct RNA polymerase
complexes, we have presented direct evidence for trans-comple-
mentation during the influenza virus RNA replication process.
These results are compatible with a new model for viral RNA
replication whereby a template RNP would be replicated in trans
by a soluble polymerase complex and the progeny RNP
encapsidation would be specified in trans by a polymerase
complex distinct from the replicative enzyme. In contrast, no
transcription in trans could be detected in vitro or in vivo and
hence we propose a model for cis-transcription of the RNPs
whereby the resident polymerase complex would be responsible
for mRNA synthesis and polyadenylation.
Materials and Methods
Biological materials
The HEK293T cell line [68] was used throughout. The origins
of plasmids pCMVPB1, pCMVPB2, pCMVPB2His, pCMVPA
and pCMVNP, as well as pHHclone 23, have been described
[20,64]. Plasmid pHHCAT was kindly provided by A. Rodriguez.
The antibodies specific for PB2 and PA have been described
[69,70]. Antibodies specific for NP were prepared by immunisa-
tion with purified His-NP protein. Mutant PB2 plasmids including
mutations in the N-terminal region [36] or the cap-binding site
[20] have been reported earlier. The mutations F130A, R142A,
E361A, H357A, K370A and F404A were transferred to
pCMVPB2 by swapping the appropriate restriction fragments.
The genotype of the mutant plasmids was verified by sequencing.
Amplification and purification of recombinant RNPs
Recombinant RNPs containing either the DNS clone 23
(248 nt) or the NSCAT (720 nt) genomic RNAs were generated
and amplified in vivo by transfection of plasmids pCMVPB1,
pCMVPB2His, pCMVPA, pCMVNP and either pHHclone23 or
pHHNSCAT into HEK293T cells, using the calcium phosphate
protocol [71]. For RNP purification, cell extracts were prepared at
24 hours post-transfection and incubated overnight at 4uC with
30 mlo fN i
2+-NTA-agarose resin in a buffer containing 50 mM
Tris-HCl-100 mM KCl-5 mM MgCl2-0.5% Igepal-20 mM imi-
dazol-1 u/ml RNAsin-EDTA-free protease inhibitors cocktail,
pH 8. The resin was washed with 100 volumes of 50 mM Tris-
HCl-100 mM KCl-5 mM MgCl2-0.5% Igepal-20 mM imidazol,
pH 8 and eluted with 50 mM Tris-HCl-100 mM KCl-0.5%
Igepal-175 mM imidazol, pH 8. Under these conditions, binding
of the progeny RNPs to the resin was quantitative, as using three-
fold excess of Ni
2+-NTA-agarose did not result in any increase in
the yield of purified RNPs (see Fig. S5).
Biochemical techniques
Western-blotting was performed as described [30]. The
replication of RNPs in vivo was determined as described [20].
In brief, cultures of HEK293T cells were transfected with plasmids
pCMVPB1, pCMVPB2His (or mutants thereof) or pCMVPB2 (or
mutants thereof), pCMVPA, pCMVNP and pHHclone 23. In
some experiments pHHclone 23 plasmid was omitted and purified
clone 23 RNPs were transfected instead, 24 hours after plasmid
transfection. Total cell extracts were prepared at 24 hours post-
transfection and used for purification by affinity chromatography
on Ni
2+-NTA-agarose as indicated above and the accumulation of
progeny RNPs was determined by Western-blot with anti-NP-
specific antibodies. The transcription of RNPs in vivo was assayed
by transfection of purified NSCAT RNPs into HEK293T cells.
The cultures were first transfected with plasmids pCMVPB1,
pCMVPB2 (or mutants thereof) and pCMVPA [20] and 24 hours
later were further transfected with purified His-tagged NSCAT
RNPs under the same conditions. At 24 hours post RNP-
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concentration was determined by ELISA (GE Healthcare).
RNA analyses
To determine the transcription activity of purified RNPs,
samples were incubated in a buffer containing 50 mM Tris-HCl-
5 mM MgCl2-100 mM KCl-1 mM DTT-10 mg/ml actinomycin
D-1 u/ml RNAsin-1 mM ATP-1 mM CTP-1 mM UTP-10 mM
a-P
32-GTP (20 mCi/mmol) and either 100 mM ApG or 10 mg/ml
b-globin mRNA, for 60 min at 30uC. The RNA synthesised was
TCA precipitated, filtered through a nylon filter in a dot-blot
apparatus and quantified in a phosphorimager. To analyse the
transcription products, similar reactions were carried out but the
specific activity of the labelled GTP was increased to 200 mCi/
mmol. The synthesised RNA was isolated by treatment with
proteinase K (50 mg/ml) for 30 min at 37uC in TNE-1% SdS and
phenol extraction. The RNA was ethanol precipitated, resus-
pended in formamide loading buffer and analysed by electropho-
resis in a 4% polyacrylamide-urea denaturing gel.
To analyse the progeny RNA, purified RNPs were incubated
with proteinase K (200 mg/ml) in a buffer containing 100 mM
NaCl-5 mM EDTA-0.5% SDS-50 mM Tris.HCl, pH 7.5 for
60 min at 37uC, phenol extracted with ethanol precipitated.
Samples of the purified RNAs were denatured by boiling for 3 min
in 7.5% formaldehyde-10SSC and were fixed onto nylon filters.
Replicate filters were hybridised at 37uC with full-length NS
riboprobes of either positive- or negative-polarity in a buffer
containing 6SSC-40% formamide-0.5% SDS-5xDenhart’s mix-
ture-100 mg/ml single-stranded DNA. After washing at 60uC with
0.1SSC-0.1%SDS, hybridisation signals were quantitated in a
phosphorimager.
Supporting Information
Figure S1 Expression of wild-type and mutant PB2 proteins.
Cultures of HEK293T cells were transfected with plasmids
encoding wt or mutant PB2 proteins, as indicated. Total cell
extracts were prepared and analysed by Western-blot using anti-
PB2 antibodies as described in Materials and Methods. The
position of the PB2-specific signals of His-tagged (PB2His) or
untagged PB2 is indicated to the right.
Found at: doi:10.1371/journal.ppat.1000462.s001 (0.30 MB TIF)
Figure S2 Intracistronic polymerase complementation during
influenza virus RNA replication. Cultures of HEK293T cells were
transfected with plasmids expressing a virus-like replicon of 248 nt,
the NP and various combinations of the polymerase subunits as
indicated (replication-defective -R142A, F130A-; transcription-
defective -H357A, K370A, F404A-). The progeny RNPs were
purified from total cell extracts over Ni-NTA-agarose resin and
analysed by Western-blot with anti-NP antibodies. The top panel
presents the accumulation of NP in the total cell extract whereas
the bottom panel shows the NP accumulation of purified RNPs. In
the bottom graph the quantitation of the data is presented as
percent of maximal value.
Found at: doi:10.1371/journal.ppat.1000462.s002 (0.59 MB TIF)
Figure S3 Phenotype of trans-complemented RNPs. The
purified RNP preparations presented in Fig. S2 were tested for
in vitro transcription primed with either ApG (red) or b-globin
mRNA (green). The data are presented as percent of maximal
value. The transcription activities parallel the values of NP
accumulation presented in Fig. S2 and show that the rescued
RNPs have a wt cap-snatching phenotype.
Found at: doi:10.1371/journal.ppat.1000462.s003 (0.51 MB TIF)
Figure S4 Control of the biological activity of transfected RNPs.
To verify the biological activity of the PB2 E361A RNPs used in
the experiments described in Fig. 7, cells were transfected with
polymerase subunits and NP-expressing plasmids and further
transfected with the purified RNPs. At 24 h post-transfection of
the latter cell extracts were prepared and the CAT protein
accumulation was determined by ELISA. As control, single
transfection with polymerase subunit and NP-expressing plasmids
was performed in parallel.
Found at: doi:10.1371/journal.ppat.1000462.s004 (0.96 MB TIF)
Figure S5 Linearity of the RNP binding to Ni
2+-NTA-agarose
resin. Cultures of HEK293T cells were transfected with plasmids
expressing PB1, PB2, PA, NP and a model vRNA template (DNS
clone 23). At 24 h post-transfection, cell extracts were prepared
and used for affinity chromatography over Ni
2+-NTA-agarose
resin as described under Materials and Methods. Aliquots of the
input extract (IN), material not bound to the resin (NB) and eluted
with imidazol (EL), were analysed by Western-blot with antibodies
specific for PA and NP. Increasing amounts of resin, 30, 60, and
100 ml were used for identical input extracts, as indicated at the
top of the Figure. The mobility of molecular weight markers (in
kDa) is shown to the left. The position of the signals specific to PA
and NP are indicated to the right.
Found at: doi:10.1371/journal.ppat.1000462.s005 (0.59 MB TIF)
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